NDAINTRAVENOUSPOWDER
Approved
Mar 2021
Lifecycle
Peak
Competitive Pressure
0/100
Mechanism of Action
12.1 Mechanism of Action Oritavancin is an antibacterial drug [see ] . 12.2 Pharmacodynamics The antimicrobial activity of oritavancin appears to correlate with the ratio of area under the concentration-time curve to minimal inhibitory concentration (AUC/MIC) based on animal models of infection.…
Indications (6)
skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptiblemethicillin-resistant isolates)Streptococcus pyogenesStreptococcus agalactiaeStreptococcus dysgalactiaeStreptococcus anginosus group (includes S
Loss of Exclusivity
LOE Date
Jul 16, 2035
114 months away
Patent Expiry
Jul 16, 2035